06.18.20
ChromaDex Corp. announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing in its quality control and research and development facility in Longmont, Colorado. This accreditation covers testing of the company’s Tru Niagen consumer products, its Niagen ingredient, and phytochemical reference standards performed out of the facility. The accreditation requires demonstration of full and continuous compliance with the most rigorous ISO quality standards.
The ISO 17025 accreditation validates the technical proficiency of the ChromDex laboratory and its ability to consistently generate highly accurate, scientifically defensible product quality data that is traceable to and compliant with international standards.
“This latest accreditation recognizes ChromaDex’s consistency in meeting the highest international standards in quality control,” ChromaDex CEO Rob Fried said. “Our global partners such as Nestlé have learned to expect these designations along with world-class clinical data.”
Niagen is the only commercially available nicotinamide riboside (NR) which has twice been successfully reviewed under U.S. Food and Drug Association’s new dietary ingredient notification requirement and successfully notified to the FDA as generally recognized as safe (GRAS). ChromaDex has also secured regulatory approval on Niagen in Canada, Australia, and in the European Union.
NR is a member of the vitamin B3 family, and is used by cells to create nicotinamide adenine dinucleotide (NAD+) which is found in every living cell. NAD+ levels tend to decline in people as they age, and it is believed that NAD+ levels may play a significant role in the aging process.
The ISO 17025 accreditation validates the technical proficiency of the ChromDex laboratory and its ability to consistently generate highly accurate, scientifically defensible product quality data that is traceable to and compliant with international standards.
“This latest accreditation recognizes ChromaDex’s consistency in meeting the highest international standards in quality control,” ChromaDex CEO Rob Fried said. “Our global partners such as Nestlé have learned to expect these designations along with world-class clinical data.”
Niagen is the only commercially available nicotinamide riboside (NR) which has twice been successfully reviewed under U.S. Food and Drug Association’s new dietary ingredient notification requirement and successfully notified to the FDA as generally recognized as safe (GRAS). ChromaDex has also secured regulatory approval on Niagen in Canada, Australia, and in the European Union.
NR is a member of the vitamin B3 family, and is used by cells to create nicotinamide adenine dinucleotide (NAD+) which is found in every living cell. NAD+ levels tend to decline in people as they age, and it is believed that NAD+ levels may play a significant role in the aging process.
